• Je něco špatně v tomto záznamu ?

Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

T. Sychra, A. Spalenkova, S. Balatka, R. Vaclavikova, K. Seborova, M. Ehrlichova, J. Truksa, C. Sandoval-Acuña, V. Nemcova, A. Szabo, K. Koci, T. Tesarova, L. Chen, I. Ojima, M. Oliverius, P. Soucek

. 2024 ; 27 (2) : 109044. [pub] 20240126

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005774

Pancreatic cancer is a severe malignancy with increasing incidence and high mortality due to late diagnosis and low sensitivity to treatments. Search for the most appropriate drugs and therapeutic regimens is the most promising way to improve the treatment outcomes of the patients. This study aimed to compare (1) in vitro efficacy and (2) in vivo antitumor effects of conventional paclitaxel and the newly synthesized second (SB-T-1216) and third (SB-T-121605 and SB-T-121606) generation taxanes in KRAS wild type BxPC-3 and more aggressive KRAS G12V mutated Paca-44 pancreatic cancer cell line models. In vitro, paclitaxel efficacy was 27.6 ± 1.7 nM, while SB-Ts showed 1.7-7.4 times higher efficacy. Incorporation of SB-T-121605 and SB-T-121606 into in vivo therapeutic regimens containing paclitaxel was effective in suppressing tumor growth in Paca-44 tumor-bearing mice at small doses (≤3 mg/kg). SB-T-121605 and SB-T-121606 in combination with paclitaxel are promising candidates for the next phase of preclinical testing.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005774
003      
CZ-PrNML
005      
20240412131009.0
007      
ta
008      
240405s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.isci.2024.109044 $2 doi
035    __
$a (PubMed)38357661
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sychra, Tomas $u Department of Surgery, University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
245    10
$a Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma / $c T. Sychra, A. Spalenkova, S. Balatka, R. Vaclavikova, K. Seborova, M. Ehrlichova, J. Truksa, C. Sandoval-Acuña, V. Nemcova, A. Szabo, K. Koci, T. Tesarova, L. Chen, I. Ojima, M. Oliverius, P. Soucek
520    9_
$a Pancreatic cancer is a severe malignancy with increasing incidence and high mortality due to late diagnosis and low sensitivity to treatments. Search for the most appropriate drugs and therapeutic regimens is the most promising way to improve the treatment outcomes of the patients. This study aimed to compare (1) in vitro efficacy and (2) in vivo antitumor effects of conventional paclitaxel and the newly synthesized second (SB-T-1216) and third (SB-T-121605 and SB-T-121606) generation taxanes in KRAS wild type BxPC-3 and more aggressive KRAS G12V mutated Paca-44 pancreatic cancer cell line models. In vitro, paclitaxel efficacy was 27.6 ± 1.7 nM, while SB-Ts showed 1.7-7.4 times higher efficacy. Incorporation of SB-T-121605 and SB-T-121606 into in vivo therapeutic regimens containing paclitaxel was effective in suppressing tumor growth in Paca-44 tumor-bearing mice at small doses (≤3 mg/kg). SB-T-121605 and SB-T-121606 in combination with paclitaxel are promising candidates for the next phase of preclinical testing.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Spalenkova, Alzbeta $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Balatka, Stepan $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Vaclavikova, Radka $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Seborova, Karolina $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Ehrlichova, Marie $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Truksa, Jaroslav $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, 252 50 Vestec, Czech Republic
700    1_
$a Sandoval-Acuña, Cristian $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, 252 50 Vestec, Czech Republic
700    1_
$a Nemcova, Vlasta $u Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
700    1_
$a Szabo, Arpad $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $u Department of Pathology University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
700    1_
$a Koci, Kamila $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
700    1_
$a Tesarova, Tereza $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
700    1_
$a Chen, Lei $u Institute of Chemical Biology & Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA
700    1_
$a Ojima, Iwao $u Institute of Chemical Biology & Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA
700    1_
$a Oliverius, Martin $u Department of Surgery, University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
700    1_
$a Soucek, Pavel $u Toxicogenomics Unit, National Institute of Public Health, 100 00 Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic
773    0_
$w MED00197302 $t iScience $x 2589-0042 $g Roč. 27, č. 2 (2024), s. 109044
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38357661 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412131001 $b ABA008
999    __
$a ok $b bmc $g 2076024 $s 1215536
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 27 $c 2 $d 109044 $e 20240126 $i 2589-0042 $m iScience $n iScience $x MED00197302
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Možnosti archivace